IPO FILING - Transkaryotic Therapies Inc . 
WASHINGTON 1996-08-27 
Company Name Transkaryotic Therapies Inc 
Nasdaq Stock symbol TKTX 
Estimated price range $ 13 - $ 15 / shr 
Total shares to be offered 2.5 million 
Shrs offered by company 2.5 million 
Shrs outstanding after ipo 16,668,560 
Lead Underwriter Morgan Stanley and Co Inc 
Underwriters over-allotment 375,000 shrs Shares to be purchased by Hoechst Marion Roussel Inc 357,143 Business : developed two proprietary technology platforms , gene activation and gene therapy . 
Use of Proceeds : Research , preclinical and clinical product development , and general corporate purposes . 
Financial Data in 000s : 1995 1994 
- Revenue $ 15,400 $ 10,000 
- Net Income ( loss ) $ 2,074 ( $ 3,422 ) 
